China's top court rebuffs 'one product, one market' approach in TCM dispute
By MLex Staff ( July 15, 2026, 06:25 GMT | Insight) -- China's Supreme People's Court has ruled that four traditional Chinese medicine products shouldn't each be treated as standalone relevant markets in an abuse-of-dominance dispute, saying courts should instead assess demand substitutability among competing medicines when defining relevant markets. The ruling dismissed a distributor's claim that a drugmaker abused its dominant position by refusing to supply medicines.China's Supreme People's Court has ruled that relevant markets for traditional Chinese medicines, or TCM, shouldn't be defined solely by their officially approved medicine names, emphasizing demand substitutability in market definition....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.